{"disease":{"id":"bevacizumab","name":"bevacizumab"},"drugs":{"marketed":[{"drug_id":"bevacizumab-maly","indication_name":"Metastatic Colorectal Cancer - Second Line Post Bevacizumab","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"ALYMSYS","generic_name":"BEVACIZUMAB-MALY","company_name":"AMNEAL PHARMS LLC","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"pf-06865571","indication_name":"Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Colorectal Cancer in adults in combination with nivolumab and ipilimumab and fluorouracil, leucovorin, irinotecan, and oxaliplatin (mFOLFOX6) and bevacizumab","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06865571","generic_name":"pf-06865571","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-1/PD-L1 pathway","drug_class":"Monoclonal antibody","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"pf-06865571","indication_name":"Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Colorectal Cancer in adults in combination with nivolumab and ipilimumab and fluorouracil, leucovorin, irinotecan, and oxaliplatin (mFOLFOX6) and bevacizumab and cetuximab","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06865571","generic_name":"pf-06865571","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-1/PD-L1 pathway","drug_class":"Monoclonal antibody","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"pf-06865571","indication_name":"Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Colorectal Cancer in adults in combination with nivolumab and ipilimumab and fluorouracil, leucovorin, irinotecan, and oxaliplatin (mFOLFOX6) and bevacizumab and cetuximab and panitumumab","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06865571","generic_name":"pf-06865571","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-1/PD-L1 pathway","drug_class":"Monoclonal antibody","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"pf-06865571","indication_name":"Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Colorectal Cancer in adults in combination with nivolumab and ipilimumab and fluorouracil, leucovorin, irinotecan, and oxaliplatin (mFOLFOX6) and bevacizumab and cetuximab and panitumumab and avelumab","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06865571","generic_name":"pf-06865571","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-1/PD-L1 pathway","drug_class":"Monoclonal antibody","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"pf-06865571","indication_name":"Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Colorectal Cancer in adults in combination with nivolumab and ipilimumab and fluorouracil, leucovorin, irinotecan, and oxaliplatin (mFOLFOX6) and bevacizumab and cetuximab and panitumumab and avelumab and pembrolizumab","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06865571","generic_name":"pf-06865571","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-1/PD-L1 pathway","drug_class":"Monoclonal antibody","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"pf-06865571","indication_name":"Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Colorectal Cancer in adults in combination with nivolumab and ipilimumab and fluorouracil, leucovorin, irinotecan, and oxaliplatin (mFOLFOX6) and bevacizumab and cetuximab and panitumumab and avelumab and pembrolizumab and nivolumab","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06865571","generic_name":"pf-06865571","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-1/PD-L1 pathway","drug_class":"Monoclonal antibody","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"pf-06865571","indication_name":"Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Colorectal Cancer in adults in combination with nivolumab and ipilimumab and fluorouracil, leucovorin, irinotecan, and oxaliplatin (mFOLFOX6) and bevacizumab and cetuximab and panitumumab and avelumab and pembrolizumab and nivolumab and ipilimumab","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06865571","generic_name":"pf-06865571","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-1/PD-L1 pathway","drug_class":"Monoclonal antibody","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"pf-06865571","indication_name":"Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Colorectal Cancer in adults in combination with nivolumab and ipilimumab and fluorouracil, leucovorin, irinotecan, and oxaliplatin (mFOLFOX6) and bevacizumab and cetuximab and panitumumab and avelumab and pembrolizumab and nivolumab and ipilimumab and fluorouracil, leucovorin, irinotecan, and oxaliplatin (mFOLFOX6)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06865571","generic_name":"pf-06865571","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-1/PD-L1 pathway","drug_class":"Monoclonal antibody","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"pf-06865571","indication_name":"Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Colorectal Cancer in adults in combination with nivolumab and ipilimumab and fluorouracil, leucovorin, irinotecan, and oxaliplatin (mFOLFOX6) and bevacizumab and cetuximab and panitumumab and avelumab and pembrolizumab and nivolumab and ipilimumab and fluorouracil, leucovorin, irinotecan, and oxaliplatin (mFOLFOX6) and avelumab","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06865571","generic_name":"pf-06865571","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-1/PD-L1 pathway","drug_class":"Monoclonal antibody","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"pf-06865571","indication_name":"Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Colorectal Cancer in adults in combination with nivolumab and ipilimumab and fluorouracil, leucovorin, irinotecan, and oxaliplatin (mFOLFOX6) and bevacizumab and cetuximab and panitumumab and avelumab and pembrolizumab and nivolumab and ipilimumab and fluorouracil, leucovorin, irinotecan, and oxaliplatin (mFOLFOX6) and avelumab and pembrolizumab","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06865571","generic_name":"pf-06865571","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-1/PD-L1 pathway","drug_class":"Monoclonal antibody","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"pf-06865571","indication_name":"Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Colorectal Cancer in adults in combination with nivolumab and ipilimumab and fluorouracil, leucovorin, irinotecan, and oxaliplatin (mFOLFOX6) and bevacizumab and cetuximab and panitumumab and avelumab and pembrolizumab and nivolumab and ipilimumab and fluorouracil, leucovorin, irinotecan, and oxaliplatin (mFOLFOX6) and avelumab and pembrolizumab and nivolumab","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06865571","generic_name":"pf-06865571","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-1/PD-L1 pathway","drug_class":"Monoclonal antibody","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"pf-06865571","indication_name":"Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Colorectal Cancer in adults in combination with nivolumab and ipilimumab and fluorouracil, leucovorin, irinotecan, and oxaliplatin (mFOLFOX6) and bevacizumab and cetuximab and panitumumab and avelumab and pembrolizumab and nivolumab and ipilimumab and fluorouracil, leucovorin, irinotecan, and oxaliplatin (mFOLFOX6) and avelumab and pembrolizumab and nivolumab and ipilimumab","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06865571","generic_name":"pf-06865571","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-1/PD-L1 pathway","drug_class":"Monoclonal antibody","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"pf-06865571","indication_name":"Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Colorectal Cancer in adults in combination with nivolumab and ipilimumab and fluorouracil, leucovorin, irinotecan, and oxaliplatin (mFOLFOX6) and bevacizumab and cetuximab and panitumumab and avelumab and pembrolizumab and nivolumab and ipilimumab and fluorouracil, leucovorin, irinotecan, and oxaliplatin (mFOLFOX6) and avelumab and pembrolizumab and nivolumab and ipilimumab and pembrolizumab","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06865571","generic_name":"pf-06865571","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-1/PD-L1 pathway","drug_class":"Monoclonal antibody","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"pf-06865571","indication_name":"Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Colorectal Cancer in adults in combination with nivolumab and ipilimumab and fluorouracil, leucovorin, irinotecan, and oxaliplatin (mFOLFOX6) and bevacizumab and cetuximab and panitumumab and avelumab and pembrolizumab and nivolumab and ipilimumab and fluorouracil, leucovorin, irinotecan, and oxaliplatin (mFOLFOX6) and avelumab and pembrolizumab and nivolumab and ipilimumab and pembrolizumab and nivolumab","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06865571","generic_name":"pf-06865571","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-1/PD-L1 pathway","drug_class":"Monoclonal antibody","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"pf-06865571","indication_name":"Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Colorectal Cancer in adults in combination with nivolumab and ipilimumab and fluorouracil, leucovorin, irinotecan, and oxaliplatin (mFOLFOX6) and bevacizumab and cetuximab and panitumumab and avelumab and pembrolizumab and nivolumab and ipilimumab and fluorouracil, leucovorin, irinotecan, and oxaliplatin (mFOLFOX6) and avelumab and pembrolizumab and nivolumab and ipilimumab and pembrolizumab and nivolumab and ipilimumab","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06865571","generic_name":"pf-06865571","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-1/PD-L1 pathway","drug_class":"Monoclonal antibody","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"pf-06865571","indication_name":"Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Colorectal Cancer in adults in combination with nivolumab and ipilimumab and fluorouracil, leucovorin, irinotecan, and oxaliplatin (mFOLFOX6) and bevacizumab and cetuximab and panitumumab and avelumab and pembrolizumab and nivolumab and ipilimumab and fluorouracil, leucovorin, irinotecan, and oxaliplatin (mFOLFOX6) and avelumab and pembrolizumab and nivolumab and ipilimumab and pembrolizumab and nivolumab and ipilimumab and pembrolizumab","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06865571","generic_name":"pf-06865571","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-1/PD-L1 pathway","drug_class":"Monoclonal antibody","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"pf-06865571","indication_name":"Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Colorectal Cancer in adults in combination with nivolumab and ipilimumab and fluorouracil, leucovorin, irinotecan, and oxaliplatin (mFOLFOX6) and bevacizumab and cetuximab and panitumumab and avelumab and pembrolizumab and nivolumab and ipilimumab and fluorouracil, leucovorin, irinotecan, and oxaliplatin (mFOLFOX6) and avelumab and pembrolizumab and nivolumab and ipilimumab and pembrolizumab and nivolumab and ipilimumab and pembrolizumab and nivolumab","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06865571","generic_name":"pf-06865571","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-1/PD-L1 pathway","drug_class":"Monoclonal antibody","quality_score":45,"revenue":null,"mechanism":""}],"pipeline":[],"offLabel":[],"totalMarketed":18,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06515678","title":"Impact of Antihypertensive Therapy on Recurrence Risk of Ovarian Cancer for Bevacizumab-associated Hypertension","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":9464,"lead_sponsor_name":"Groupe Hospitalier Pitie-Salpetriere","has_results":false},{"nct_id":"NCT07495735","title":"Intelligence System for Predicting Atezolizumab-Bevacizumab Response and Clinical Outcomes in Unresectable Hepatocellular Carcinoma","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":400,"lead_sponsor_name":"First Affiliated Hospital of Wenzhou Medical University","has_results":false},{"nct_id":"NCT06023173","title":"Deep Radiomics-based Fusion Model Predicting Bevacizumab Treatment Response and Outcome in Patients With Colorectal Liver Metastases","phase":"","overall_status":"COMPLETED","enrollment_count":307,"lead_sponsor_name":"Fudan University","has_results":false},{"nct_id":"NCT06323382","title":"Locoregional Therapy Combined With Bevacizumab and PD1/L1 Inhibitor in Advanced Hepatocellular Carcinoma","phase":"","overall_status":"RECRUITING","enrollment_count":240,"lead_sponsor_name":"Sun Yat-sen University","has_results":false},{"nct_id":"NCT07481786","title":"Bevacizumab Plus FSRT Versus Hippocampus-Avoidant WBRT in Lung Adenocarcinoma With Extensive Brain Metastases","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":220,"lead_sponsor_name":"Sun Yat-sen University","has_results":false},{"nct_id":"NCT05763277","title":"Ate-Bev Early Response Prediction Model in Advanced HCC","phase":"","overall_status":"RECRUITING","enrollment_count":170,"lead_sponsor_name":"Seoul National University Hospital","has_results":false},{"nct_id":"NCT06416683","title":"Atezolizumab and Bevacizumab Combination Recommended in a Multidisciplinary Consultation Meeting in Caen for Hepatocellular Carcinoma (ABCHCaen)","phase":"","overall_status":"COMPLETED","enrollment_count":109,"lead_sponsor_name":"University Hospital, Caen","has_results":false},{"nct_id":"NCT04788381","title":"The Effects of Preoperative Bevacizumab on Perioperative Complications","phase":"","overall_status":"UNKNOWN","enrollment_count":100,"lead_sponsor_name":"Second Affiliated Hospital, School of Medicine, Zhejiang University","has_results":false},{"nct_id":"NCT06265350","title":"Cryoablation Combined With Cardonilizumab and Bevacizumab in Hepatocellular Carcinoma With Pulmonary Metastases","phase":"NA","overall_status":"RECRUITING","enrollment_count":80,"lead_sponsor_name":"Sun Yat-sen University","has_results":false},{"nct_id":"NCT05970666","title":"Single Arm, Prospective, Multicenter Clinical Study of TACE With Adebrelimab and Bevacizumab for Unresectable Hepatocellular Carcinoma","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":71,"lead_sponsor_name":"The First Affiliated Hospital of Xiamen University","has_results":false},{"nct_id":"NCT06755684","title":"Neoadjuvant Befotertinib Combined Bevacizumab or Platinum-based Double Chemotherapy for Resectable Locally-advanced EGFR Mutation-positive Non-Small Cell Lung Cancer","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":60,"lead_sponsor_name":"Peng Zhang","has_results":false},{"nct_id":"NCT06539559","title":"Efficacy and Resistant Mechanism of Eribulin and Bevacizumab for Advanced HER2 Negative Breast Cancer","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":60,"lead_sponsor_name":"Wang Jiayu","has_results":false},{"nct_id":"NCT05410938","title":"Intraperitoneal Chemotherapy Versus Triweekly Chemotherapy","phase":"","overall_status":"COMPLETED","enrollment_count":59,"lead_sponsor_name":"Far Eastern Memorial Hospital","has_results":false},{"nct_id":"NCT07085169","title":"Low-dose Trifluridine/Tipiracil With Bevacizumab in mCRC","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":50,"lead_sponsor_name":"Ruijin Hospital","has_results":false},{"nct_id":"NCT05310344","title":"Albumin-bound Paclitaxel and Bevacizumab for Platinum-resistant Recurrent Ovarian Cancer","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":50,"lead_sponsor_name":"Lei Li","has_results":false},{"nct_id":"NCT05807893","title":"Study to Evaluate the Safety and Efficacy of Serplulimab Plus Bevacizumab and Chemotherapy in NSCLC Patients With Brain Metastases","phase":"PHASE2, PHASE3","overall_status":"COMPLETED","enrollment_count":40,"lead_sponsor_name":"Sun Yat-sen University","has_results":false},{"nct_id":"NCT07004335","title":"Efficacy and Safety of Iparomlimab and Tuvonralimab Injection in Combination With Bevacizumab After Progression on Anti-PD-(L)1 Therapy in Advanced Melanoma: A Prospective, Single-Arm, Exploratory Clinical Study","phase":"PHASE4","overall_status":"NOT_YET_RECRUITING","enrollment_count":40,"lead_sponsor_name":"Hebei Medical University Fourth Hospital","has_results":false},{"nct_id":"NCT07327788","title":"QL1706 in Combination With Bevacizumab and RALOX HAIC for Hepatocellular Carcinoma With Vp3/4 PVTT","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":38,"lead_sponsor_name":"Nanfang Hospital, Southern Medical University","has_results":false},{"nct_id":"NCT05263947","title":"Bevacizumab Combined With Double Doses of Icotinib in Advanced NSCLC Patients With EGFR L858R Mutation","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":35,"lead_sponsor_name":"Tianjin Medical University Cancer Institute and Hospital","has_results":false},{"nct_id":"NCT04556071","title":"Efficacy and Safety of Niraparib Combined With Bevacizumab in Platinum Refractory/Resistant Recurrent Ovarian Cancer","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":32,"lead_sponsor_name":"Xiaoxiang Chen","has_results":false},{"nct_id":"NCT04627363","title":"HAIC Combined With Bevacizumab and Toripalimab for Advanced Hepatocellular Carcinama","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":30,"lead_sponsor_name":"Sun Yat-sen University","has_results":false},{"nct_id":"NCT06609863","title":"dTACE-HAIC Combined With Bevacizumab and Atezolizumab for Huge Hepatocellular Carcinoma","phase":"NA","overall_status":"RECRUITING","enrollment_count":27,"lead_sponsor_name":"Sun Yat-sen University","has_results":false},{"nct_id":"NCT03842917","title":"SAlt Diet and Various Biomarkers Effects on Blood Pressure and Proteinuria During Inhibition of VEGF)","phase":"","overall_status":"COMPLETED","enrollment_count":26,"lead_sponsor_name":"University Hospital, Tours","has_results":false},{"nct_id":"NCT05111860","title":"Neoadjuvant Bevacizumab + Chemotherapy Combined With Short-course Radiotherapy","phase":"PHASE1, PHASE2","overall_status":"UNKNOWN","enrollment_count":20,"lead_sponsor_name":"Shanghai Minimally Invasive Surgery Center","has_results":false},{"nct_id":"NCT07011550","title":"Phase 2, Single-arm Trial of BMS-986340 in Association With Nivolumab, Trifluridine/Tipiracil and Bevacizumab for Patients Refractory to Standard of Care Treatment and With Microsatellite-stable Colorectal Cancer","phase":"PHASE2","overall_status":"SUSPENDED","enrollment_count":7,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false}],"total":25},"guidelines":[],"source":"Drug Landscape verified database"}